Arvelle Therapeutics Licenses Exclusive Development & Commercialization Rights for Cenobamate from SK Biopharmaceuticals in EU
Shots:
- SK Biopharmaceuticals to receive $100M upfront- $430M milestones- and royalties on sales of product. Arvelle to get exclusive rights to develop and commercialize SK’s Cenobamate in EU
- SK also has an option to make equity investment in Arvelle and will retain WW commercialization rights for Cenobamate (Ex-EU). Arvelle plans to file Cenobamate’s MAA to EU based on the trial conducted by SK- for partial-onset seizures in adults
- Cenobamate (YKP3089) is an antiepileptic drug involved in modulating GABA-A receptor and has received NDA approval from the US FDA for partial-onset seizures in adults in Feb- 2019
Ref: GlobeNewwire | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com